Alcoholic Liver Disease (ALD)
At a Glance
No biochemical markers pathognomonic for alcoholic liver disease (ALD) exist. The diagnosis has to start with evidence of alcohol abuse either from a history of documented blood alcohol levels or from response to one of the questionnaires desired to elicit a history of ongoing alcohol abuse.
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
Historically, gamma glutamyl transpeptidase (GGT) has been used as a screening tool for alcoholism.
Another, relatively specific marker for ALD is carbohydrate deficient transferrin (CDT).
Elevations of aspartate aminotransferase up to six times the upper limit of normal and alanine aminotransferase up to 5 times its upper limit of normal is consistent with alcohol abuse, especially with a ratio greater than 2:1. A ratio of 3:1 has a sensitivity of 90% for the diagnosis.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
The Cardiology Advisor Articles
- Does Pre-Existing PH Affect Outcomes in Transcatheter Mitral Valve Repair?
- How Has the Medicaid Expansion Affected Patients Hospitalized With Acute MI?
- Macitentan Not Superior to Placebo for Improving Exercise Capacity in Eisenmenger Syndrome
- Occupational Metal, Pesticide Exposure May Be Associated With Increased CVD Risk
- FDA to Review Tafamidis for Treatment of Transthyretin Amyloid Cardiomyopathy
- ASH Develops Practice Guidelines for Venous Thromboembolism
- Tetralogy of Fallot: Long-Term Outcomes After Surgical Repair
- Stethoscopes in ICU Show High Levels of Bacterial Contamination
- Catheter Ablation Superior to Drug Therapy for Atrial Fibrillation in Heart Failure
- Trends in Endocarditis Incidence After Implementation of 2007 AHA Recommendations
- Researchers Identify Golden Ratio Between Pulmonary Pressure Components in PAH
- FDA: Potential Increased Mortality With Paclitaxel-Coated Balloons, Stents for PAD
- Inhaled Dry Powder Formulation of Treprostinil Well Tolerated in PAH
- Elevated Myocardial T1 Associated With Increased Septal Angle in PAH
- Pulmonary Hypertension Intensive Care Options Depend on Treatment Goals